Mechanism of action of bitopertin to treat patients with EPP

Описание к видео Mechanism of action of bitopertin to treat patients with EPP

William Savage, MD, PhD, Disc Medicine, Watertown, MA, comments on the mechanism of action of bitopertin, an oral and selective inhibitor of glycine type 1 (GlyT1), which is currently being developed for the treatment of erythropoietic protoporphyria (EPP). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео